General Information:

Id: 3,890 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Fatty liver disease, nonalcoholic
Insulin resistance
Metabolic syndrome
Reference: Matikainen N and Taskinen MR(2012) Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes Curr Cardiol Rep 14: 721-731 [PMID: 22941588]

Interaction Information:

Comment Statins are the most powerful agents to decrease plasma concentrations of LDL-C and apoB but their impact on plasma TG and HDL-C concentrations is less robust. Fibrates have been demonstrated to improve all components of diabetic dyslipidemia. Therefore, it would be rational to use fibrates as an add-on therapy on top of statins to reduce the residual risk in MetS and diabetes.
Formal Description
Interaction-ID: 39332

drug/chemical compound


NOT affects_activity of